News

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Researchers found that high levels of AST and ALT in patients with acne taking oral isotretinoin was low in incidence.

Currently, some United States Pharmacopeia carbomer monographs allow unacceptable levels of benzene

To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists.

Researchers say that application of these findings in clinical settings could enhance treatment optimization.

The integration of digital tools, including telemedicine, into routine clinical care is not without its hurdles.

In this week’s Pointers With Portela, the 208SkinDoc reviews 7 different methods to treat acne without isotretinoin.

Winter Editor in Chief Christopher Bunick, MD, PhD, looks ahead to a year of dermatology innovations with a reflection on meaningful advances from 2023.

Researchers said this data is demonstrative of VYN201's positive effects on multiple vitiligo-related biomarkers.

Study findings suggest that Lavandula species, with their historical use in folk medicine, could emerge as valuable additions to AD treatment regimens. However, it's crucial to note that the efficacy of these oils is concentration-dependent.

Test your knowledge and explore a recent study on the relationship between alcohol consumption and skin diseases, including atopic dermatitis.

Researchers compared the quality of life, anxiety, depression, sleep disturbance, and other associated factors between patients with alopecia areata and vitiligo.

A randomized, placebo-controlled trial of the selective transient receptor potential melastatin 8 agonist explored its efficacy and safety in PN.

Dermatology Times is excited to ring in 2024 with a fresh perspective to amplify our impact, foster creativity, and deliver even more exceptional, compelling content to you—our cherished audience.

This week’s collection of the latest dermatologic studies covers ligelizumab for the treatment of chronic spontaneous urticaria, AI for the early detection of skin cancer, blood pressure monitoring for minoxidil therapy in alopecia patients, and aminolevulinic acid 20% solution plus blue light PDT for the treatment of AKs.

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Researchers analyzed the characteristics of Wood's lamp and reflective confocal laser scanning microcopy in guiding vitiligo staging.

The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.

Higher response rates were observed in patients treated with lutikizumab. The drug will now advance to phase 3 clinical trials.

A meta-analysis revealed that a post-operative care routine that involves psychological well-being leads to improved patient outcomes.

Keep up with the latest headlines in dermatology from the past week, including a successful year for the Skin of Color Society, a rise in skin clinic visits attributed to carbon monoxide levels, and more.

ICYMI, this week we had articles about a CME credit opportunity on the pathogenesis of HS, Paul Friedman, MD, reviewing UltraClear Laser-Coring, Journey Medical Corporation submitting its NDA for DFD-29 for the treatment of rosacea, and more.

The approval marks a milestone for patients ages 1 year of age and older who face the persistent, highly contagious condition.

Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.

The last patient has been dosed in the trial of the potential first-in-class oncolytic peptide for BCC.

The pilot study explored the use of double-conjugated retinoid serum used in combination with exfoliating peel pads.

The filing is supported by positive phase 3 clinical trial data.

In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.

Soligenix shared today positive top-line data stemming from the phase 2a clinical trial.

The Type C meeting held this past December involved discussion of a phase 3 clinical development plan for Ycanth in the treatment of common warts.